United States Biotechnology & Medical Research

Decibel Therapeutics Inc (DBTX)

Track

Decibel Therapeutics Inc. has not recorded any insider trading activity in the last three months. The most recent transactions occurred in January 2022, consisting of planned sales by insider Anna Trask. Prior to this, the company saw various buy transactions from executives and institutional investors throughout 2021.
Ticker: DBTX Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Decibel Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Trask Anna
See Remarks
2 sales — total 1,901 USD
Planned sale 3 Jan 2022
Value US$798,833.72 | Price 275.53 | Shares 79,250
Planned sale 3 Jan 2022
Value US$3,990,790.37 | Price 49.24 | Shares 73,435
Planned sale 2 Dec 2021
Value US$3,772,190.35 | Price 369.55 | Shares 6,141
Planned sale 2 Dec 2021
Value US$2,913,449.65 | Price 478.87 | Shares 4,196
Planned sale 3 Nov 2021
Value US$3,152.22 | Price 8.34 | Shares 378
Planned sale 2 Nov 2021
Value US$40,827.03 | Price 8.31 | Shares 4,913
Planned sale 14 Oct 2021
Value US$40,481.04 | Price 7.55 | Shares 5,364
Buy 15 Sep 2021
Value US$76,400.00 | Price 7.64 | Shares 10,000
Buy 17 Feb 2021
Value US$2,700,000.00 | Price 18.00 | Shares 150,000
Buy 17 Feb 2021
Value US$2,700,000.00 | Price 18.00 | Shares 150,000
Buy 17 Feb 2021
Value US$10,000,188.00 | Price 18.00 | Shares 555,566
Buy 17 Feb 2021
Value US$19,999,800.00 | Price 18.00 | Shares 1,111,100
Buy 17 Feb 2021
Value US$10,350,000.00 | Price 18.00 | Shares 575,000
Buy 17 Feb 2021
Value US$10,000,188.00 | Price 18.00 | Shares 555,566
Buy 17 Feb 2021
Value US$19,999,800.00 | Price 18.00 | Shares 1,111,100
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2022-01-04 2022-01-03 PlS Planned sale
Trask Anna

See Remarks

Officer
79,250 +12.4%
275.53
US$798,834 		79,250 +12.4% 275.53 US$798,834
2022-01-04 2022-01-03 PlS Planned sale
Trask Anna

See Remarks

Officer
73,435 +2.4%
49.24
US$3,990,790 		73,435 +2.4% 49.24 US$3,990,790
2021-12-06 2021-12-02 PlS Planned sale
Trask Anna

See Remarks

Officer
6,141 -7.4%
369.55
US$3,772,190 		6,141 -7.4% 369.55 US$3,772,190
2021-12-06 2021-12-02 PlS Planned sale
Trask Anna

See Remarks

Officer
4,913 -65.2%
6.37
US$31,293 		4,913 -65.2% 6.37 US$31,293
2021-11-04 2021-11-03 PlS Planned sale
Trask Anna

See Remarks

Officer
378 -4.8%
8.34
US$3,152 		378 -4.8% 8.34 US$3,152
2021-11-03 2021-11-02 PlS Planned sale
Trask Anna

SEE REMARKS

Officer
4,913 -38.3%
8.31
US$40,827 		4,913 -38.3% 8.31 US$40,827
2021-10-15 2021-10-14 PlS Planned sale
Trask Anna

See Remarks

Officer
5,364 -29.5%
7.55
US$40,481 		5,364 -29.5% 7.55 US$40,481
2021-09-17 2021-09-15 B Purchase
0.8
Reid Laurence

President and Chief Executive

Executive Director
10,000 +63.1%
7.64
US$76,400 		10,000 +63.1% 7.64 US$76,400
2021-02-19 2021-02-17 B Purchase
0.5
Foy Matthew
Non-Executive Director Large shareholder
150,000 +14.5%
18.00
US$2,700,000 		150,000 +14.5% 18.00 US$2,700,000
2021-02-19 2021-02-17 B Purchase
2.3
GLAXOSMITHKLINE PLC
Non-Executive Director
150,000 +14.5%
18.00
US$2,700,000 		150,000 +14.5% 18.00 US$2,700,000
2021-02-19 2021-02-17 B Purchase
3.0
Thompson Peter A.
Non-Executive Director Large shareholder
555,566 +169.5%
18.00
US$10,000,188 		555,566 +169.5% 18.00 US$10,000,188
2021-02-19 2021-02-17 B Purchase
3.0
Thompson Peter A.
Non-Executive Director Large shareholder
1,111,100 +40.7%
18.00
US$19,999,800 		1,111,100 +40.7% 18.00 US$19,999,800
2021-02-19 2021-02-17 B Purchase
3.3
Casdin Partners Master Fund, L.P.
Large shareholder
575,000 +105.2%
18.00
US$10,350,000 		575,000 +105.2% 18.00 US$10,350,000
2021-02-19 2021-02-17 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
555,566 +169.5%
18.00
US$10,000,188 		555,566 +169.5% 18.00 US$10,000,188
2021-02-19 2021-02-17 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
1,111,100 +40.7%
18.00
US$19,999,800 		1,111,100 +40.7% 18.00 US$19,999,800
Explore more

More insider trading research around Decibel Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America